Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Long term vagal stimulation in patients with advanced heart failure. First experience in man
European Journal of Heart Failure, Volume 10, No. 9, Year 2008
Notification
URL copied to clipboard!
Description
Background: Experimentally, vagal stimulation (VS) is protective in chronic heart failure (HF). In man, VS is used in refractory epilepsy but has never been used in cardiovascular diseases. Increased sympathetic and reduced vagal activity predict increased mortality in HF. Aims: This pilot study assessed feasibility and safety and tested possible efficacy of chronic VS in HF patients. Methods: We studied 8 patients (mean age 54 years). CardioFit (BioControl Medical), a VS implantable system delivering pulses synchronous with heart beats through a multiple contact bipolar cuff electrode, was used. VS was started 2-4 weeks after implant, slowly raising intensity; patients were followed 1, 3 and 6 months thereafter. Results: All procedures were successful: as sole surgical side effect, one patient had transient hoarseness. VS was well tolerated, with only mild side effects (cough and sensation of electrical stimulation). There was a significant improvement in NYHA class, Minnesota quality of life® (from 52 ± 14 to 31 ± 18, p < 0.001), left ventricular end-systolic volume (from 208 ± 71 to 190 ± 83 ml, p = 0.03), and a favourable trend toward reduction in end-diastolic volume. Conclusions: This novel approach to the treatment of patients with HF is feasible, and appears safe and tolerable. The preliminary efficacy results appear promising. These findings suggest the opportunity to proceed with a larger multicentre study. © 2008 European Society of Cardiology.
Authors & Co-Authors
Schwartz, Peter J.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Italy, Pavia
Università Degli Studi Di Pavia
Italy, Milan
Irccs Istituto Auxologico Italiano
South Africa, Cape Town
Hatter Institute for Cardiovascular Research
De Ferrari, Gaetano Maria
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Sanzo, Antonio
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Italy, Pavia
Università Degli Studi Di Pavia
Landolina, Maurizio
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Rordorf, R.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Raineri, Claudia
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Campana, Carlo
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Revera, Miriam
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Ajmone-Marsan, Nina
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Tavazzi, Luigi T.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Odero, Attilio
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Italy, Pavia
Università Degli Studi Di Pavia
Statistics
Citations: 284
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1016/j.ejheart.2008.07.016
ISSN:
13889842
Research Areas
Disability
Health System And Policy
Mental Health
Noncommunicable Diseases